WELCOME TO CONFIDENCE, EXTENDED

EYLEA 8 mg is the first and only anti-VEGF in nAMD and DMO that allows for extensions up to Q20*, with a safety profile comparable to EYLEA 2 mg. So you can confidently extend treatment intervals to help optimise your clinic's capacity.^1–5

EYLEA 114.3 mg/mL is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).⁵

EYLEA 8 mg

The number of people living with sight loss (of any cause) in the UK is increasing and pressure on ophthalmology services has been consistently rising in recent years due to growing treatment demand.^6,7 Clinic capacity in NHS retinal clinics is a major obstacle to delivering optimal care to nAMD and DMO patients.^6,8

What would it mean for patients in your clinic to achieve longer treatment intervals than is currently possible?

*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q20 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.⁵

Abbreviations

DMO, diabetic macular oedema. MoA, mechanism of action. nAMD, neovascular (wet) age-related macular degeneration. Q16, every 16 weeks. Q20, every 20 weeks. T&E, treat and extend. VEGF, vascular endothelial growth factor.

References

1. Korobelnik J-F. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial. Retina Society. 2–5 November 2022. Pasadena, USA. Oral presentation.
2. Do D. Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial. ARVO. 23–27 April 2023. Palo Alto, USA. Oral presentation.
3. Lanzetta P, et al. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 60-week and 96-week results from the Phase 3 PULSAR trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
4. Wykoff CC. Aflibercept 8 mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
5. EYLEA® 114.3 mg/mL Summary of Product Characteristics.
6. Gale RP, et al. Eye 2019. DOI: 10.1038/s41433-018-0300-3.
7. The Royal College of Ophthalmologists. RCOphth calls for action on workforce to reduce strain on ophthalmology services. Available at: https://www.rcophth.ac.uk/news-views/rcophth-calls-for-action-on-workforce-to-reduce-strain/. Accessed: September 2024.
8. Ross AH, et al. Eye 2020. DOI: 10.1038/s41433-019-0747-x.